Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Taselisib with fulvestrant slows growth of advanced breast cancer

2018 ASCO Annual Meeting

Published: 2 Jun 2018

Views: 1430

Rating:

Save

Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Baselga presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from a phase III trial of taselisib, a PI3K targeted therapy, used in combination with hormone therapy fulvestrant.

He describes how the combination halted the growth of advanced breast cancer growth by 2 months longer than hormone therapy alone, and decreased the chance of cancer worsening by 30%.

For more on these results, read our news coverage here.

Slides from this presentation are available here.

Related Videos

Breast cancer

Dr Sofia Rivera - Gustave Roussy, Villejuif, France

Breast cancer ( Dr Sofia Rivera - Gustave Roussy, Villejuif, France )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer ( Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal )

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC

Dr Neil Gross - MD Anderson Cancer Center, Houston, USA

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC ( Dr Neil Gross - MD Anderson Cancer Center, Houston, USA )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

The Southeast Asian Breast Cancer Symposium; background, aims and successes

Carolyn Taylor - Executive Director, Global Focus on Cancer

The Southeast Asian Breast Cancer Symposium; background, aims and successes ( Carolyn Taylor - Executive Director, Global Focus on Cancer )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert Round Up for August 11th - 17th, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 11th - 17th, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

More from ecancer